HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $190
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Axsome Therapeutics (NASDAQ:AXSM) but lowers the price target from $200 to $190.
July 17, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Axsome Therapeutics' price target has been lowered from $200 to $190 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The news is directly related to Axsome Therapeutics and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100